Video

Ari Green, MD

Publish date: April 5, 2018

Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the development of potential remyelinating therapies and a recent trial of clemastine fumarate in patients with multiple sclerosis and chronic demyelinating optic neuropathy.

 

Recommended Reading

Natalizumab May Be Associated With Increased Disease Activity During Pregnancy
ICYMI Multiple Sclerosis
Siponimod trial ‘first’ to show delayed disability in secondary progressive MS
ICYMI Multiple Sclerosis
Are Complementary and Alternative Treatments Effective for MS?
ICYMI Multiple Sclerosis
Frankincense extract may reduce disease activity in relapsing-remitting MS
ICYMI Multiple Sclerosis
Extended-Interval Dosing of Natalizumab Is Associated With Reduced PML Risk
ICYMI Multiple Sclerosis
MicroRNA Could Be a Biomarker of MS
ICYMI Multiple Sclerosis
Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
ICYMI Multiple Sclerosis
What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
ICYMI Multiple Sclerosis
High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
ICYMI Multiple Sclerosis
Clean-Surfaced Nanocrystalline Gold May Promote Remyelination
ICYMI Multiple Sclerosis

Related Articles